

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	Not Yet Assigned	
			Filing Date	Herewith	
			First Named Inventor	M. Zheng	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	1300-0013

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
/AB/	AA	5,681,702	10/28/97	Collins et al			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
/AB/	AB	BERGER, et al., "Universal bases for hybridization, replication and chain termination," Nucleic Acids Res. 28:2911-2914 (2000).		
	AC	BUSHNELL, et al., "ProbeDesigner: for the design of probesets for branched DNA (bdNA) signal amplification assays," Bioinformatics 15:348-355 (1999).		
	AD	BUSTIN, "Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays," J. Mol. Endocrinol. 25:169-193 (2000).		
	AE	COLLINS, et al., "A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml," Nucleic Acids Res. 25:2979-2984 (1997).		
	AF	de JAGER, et al., "Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells," Clin. Diag. Lab. Immunol. 10:133-139 (2003).		
	AG	ELBEIK, et al., "Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 nad Roche PCR amplicor monitor version 1.5," J. Clin. Microbiol. 38:1113-1120 (2000).		
	AH	GERMER, et al., "Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0 and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus in serum," J. Clin. Microbiol. 40:495-500 (2002).		
	AI	HIGHBARGER, et al., "Comparison of the quantiplex version 3.0 assay and a sensitized amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples," J. Clin. Microbiol. 37:3612-3614 (1999).		
	AJ	HILDESHEIM, et al., "Simultaneous measurement of several cytokines using small volumes of biospecimens," Cancer Epidemiol. Biomarkers Prev. 11:1477-1484 (2002).		
	AK	HORN, et al., "An improved divergent synthesis of comb-type branched oligodeoxyribonucleotides (bdNA) containing multiple secondary sequences," Nucleic Acids Res. 25:4835-4841 (1997).		
	AL	HORN, et al., "Chemical synthesis and characterization of branched oligodeoxyribonucleotides (bdNA) for use as signal amplifiers in nucleic acid quantification assays," Nucleic Acids Res. 25:4842-4849 (1997).		
	AM	HORN and URDEA, "Forks and combs and DNA: the synthesis of branched oligodeoxyribonucleotides," Nucleic Acids Res. 17:6959-6967 (1989).		
	AN	IANNONE, et al., "Multiplexed single nucleotide polymorphism genotyping by oligonucleotide ligation and flow cytometry," Cytometry 39:131-140 (2000).		
	AO	KERN, et al., "An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma," J. Clin. Microbiol. 34:3196-3202 (1996).		
	AP	LINDROOS, et al., "Multiplex SNP genotyping in pooled DNA samples by a four-colour microarray system," Nucleic Acids Res. 30:e70-e78 (2002).		
	AQ	LINDSTROM and KOOL, "An orthogonal oligonucleotide protecting group strategy that enables assembly of repetitive of highly structured DNA's," Nucleic Acids Res. 30:e101-e105 (2002).		
/AB/	AR	NARGESSI, et al., "Quantitation of estrogen receptor mRNA in breast carcinoma by branched DNA assay," Breast Cancer Res. Treat. 50:47-55 (1998).		

Examiner Signature	/Angela Bertagna/	Date Considered	04/26/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Herewith
				First Named Inventor	M. Zheng
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	1300-0013

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/AB/	AS	NURMI, et al., "A new label technology for the detection of specific polymerase chain reaction products in a closed tube," Nucleic Acids Res. 28:e28-e33 (2000).	
/AB/	AT	SHEN, et al., "Quantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technology," J. Immunol. Met. 215:123-134 (1998).	

Examiner Signature	/Angela Bertagna/	Date Considered	04/26/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet 1 of 1

Application Number 11049465

Filing Date 2005-02-01

First Named Inventor Minxue Zheng

Art Unit 1648

Examiner Name Bao Q. Li

Attorney Docket Number 71300-013

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/AB/	1	COLLINS et al., A Branched DNA Signal Amplification Assay for Quantification of Nucleic Acid Targets Below 100 molecules/mL, NUCLEIC ACIDS RESEARCH 25 (15):2979-2984 (1997).	
/AB/	2	IANNONE et al., Multiplexed Single Nucleotide Polymorphism Genotyping by Oligonucleotide Ligation and Flow Cytometry, CYTOMETRY 39(2):131-140 (2000).	
/AB/	3	SHEN et al., Quantification of Cytokine mRNA in Peripheral Blood Mononuclear Cells Using Branched DNA (bdNA) Technology, JOURNAL OF IMMUNOLOGICAL METHODS 215 (1-2):123-134 (1998).	

Examiner  
Signature

/Angela Bertagna/

Date  
Considered

04/26/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.